Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;30(4):320-325.
doi: 10.1097/MOL.0000000000000616.

Role of serum amyloid A in atherosclerosis

Preetha Shridas  1   2   3 , Lisa R Tannock  1   2   3   4
Affiliations
Review

Role of serum amyloid A in atherosclerosis

Preetha Shridas et al. Curr Opin Lipidol. 2019 Aug.

Abstract

Purpose of review: Acute phase serum amyloid A (SAA) is persistently elevated in chronic inflammatory conditions, and elevated levels predict cardiovascular risk in humans. More recently, murine studies have demonstrated that over-expression of SAA increases and deficiency/suppression of SAA attenuates atherosclerosis. Thus, beyond being a biomarker, SAA appears to play a causal role in atherogenesis. The purpose of this review is to summarize the data supporting SAA as a key player in atherosclerosis development.

Recent findings: A number of pro-inflammatory and pro-atherogenic activities have been ascribed to SAA. However, the literature is conflicted, as recombinant SAA, and/or lipid-free SAA, used in many of the earlier studies, do not reflect the activity of native human or murine SAA, which exists largely lipid-associated. Recent literatures demonstrate that SAA activates the NLRP3 inflammasome, alters vascular function, affects HDL function, and increases thrombosis. Importantly, SAA activity appears to be regulated by its lipid association, and HDL may serve to sequester and limit SAA activity.

Summary: SAA has many pro-inflammatory and pro-atherogenic activities, is clearly demonstrated to affect atherosclerosis development, and may be a candidate target for clinical trials in cardiovascular diseases.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None.

References

    1. Tannock LR, De Beer MC, Ji A et al. Serum amyloid A3 is a high density lipoprotein-associated acute-phase protein. J Lipid Res 2018; 59:339–347. - PMC - PubMed

    2. This study demonstrates that SAA3 can be found circulating and on HDL in mice.

    1. Sjoholm K, Palming J, Olofsson LE et al. A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 2005; 90:2233–2239. - PubMed
    1. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 1998; 46:1377–1384. - PubMed
    1. Johnson BD, Kip KE, Marroquin OC et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109:726–732. - PubMed
    1. Kosuge M, Ebina T, Ishikawa T et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J 2007; 71:186–190. - PubMed

Publication types